MBIO
Price
$1.02
Change
-$0.01 (-0.97%)
Updated
Jun 27 closing price
Capitalization
4.47M
NXTC
Price
$0.45
Change
-$0.01 (-2.17%)
Updated
Jun 27 closing price
Capitalization
12.62M
31 days until earnings call
Interact to see
Advertisement

MBIO vs NXTC

Header iconMBIO vs NXTC Comparison
Open Charts MBIO vs NXTCBanner chart's image
Mustang Bio
Price$1.02
Change-$0.01 (-0.97%)
Volume$172.48K
Capitalization4.47M
NextCure
Price$0.45
Change-$0.01 (-2.17%)
Volume$175.86K
Capitalization12.62M
MBIO vs NXTC Comparison Chart in %
Loading...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MBIO vs. NXTC commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBIO is a Buy and NXTC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (MBIO: $1.02 vs. NXTC: $0.46)
Brand notoriety: MBIO and NXTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBIO: 32% vs. NXTC: 74%
Market capitalization -- MBIO: $4.47M vs. NXTC: $12.62M
MBIO [@Biotechnology] is valued at $4.47M. NXTC’s [@Biotechnology] market capitalization is $12.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBIO’s FA Score shows that 0 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • MBIO’s FA Score: 0 green, 5 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, NXTC is a better buy in the long-term than MBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBIO’s TA Score shows that 3 TA indicator(s) are bullish while NXTC’s TA Score has 3 bullish TA indicator(s).

  • MBIO’s TA Score: 3 bullish, 6 bearish.
  • NXTC’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both MBIO and NXTC are a bad buy in the short-term.

Price Growth

MBIO (@Biotechnology) experienced а -2.86% price change this week, while NXTC (@Biotechnology) price change was -2.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

NXTC is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NXTC($12.6M) has a higher market cap than MBIO($4.47M). NXTC YTD gains are higher at: -40.700 vs. MBIO (-88.475). MBIO has higher annual earnings (EBITDA): -10.6M vs. NXTC (-50.34M). NXTC has more cash in the bank: 55.9M vs. MBIO (14.2M). MBIO has less debt than NXTC: MBIO (0) vs NXTC (4.91M). MBIO (0) and NXTC (0) have equivalent revenues.
MBIONXTCMBIO / NXTC
Capitalization4.47M12.6M35%
EBITDA-10.6M-50.34M21%
Gain YTD-88.475-40.700217%
P/E RatioN/AN/A-
Revenue00-
Total Cash14.2M55.9M25%
Total Debt04.91M-
FUNDAMENTALS RATINGS
MBIO vs NXTC: Fundamental Ratings
MBIO
NXTC
OUTLOOK RATING
1..100
526
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9588
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (13) in the Biotechnology industry is significantly better than the same rating for MBIO (91) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew significantly faster than MBIO’s over the last 12 months.

NXTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to MBIO’s over the last 12 months.

NXTC's SMR Rating (100) in the Biotechnology industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to MBIO’s over the last 12 months.

NXTC's Price Growth Rating (88) in the Biotechnology industry is in the same range as MBIO (95) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to MBIO’s over the last 12 months.

NXTC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to MBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBIONXTC
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LCII91.951.44
+1.59%
LCI Industries
WBD11.300.15
+1.35%
Warner Bros Discovery
SPTN26.510.11
+0.42%
SpartanNash Company
ASMB17.31N/A
N/A
Assembly Biosciences
OTRK0.97N/A
N/A
Ontrak Inc

MBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBIO has been loosely correlated with SLRX. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if MBIO jumps, then SLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBIO
1D Price
Change %
MBIO100%
-0.97%
SLRX - MBIO
63%
Loosely correlated
-0.01%
IPHYF - MBIO
42%
Loosely correlated
N/A
SCNI - MBIO
37%
Loosely correlated
-7.69%
MIRM - MBIO
34%
Loosely correlated
+1.05%
GLSI - MBIO
32%
Poorly correlated
N/A
More

NXTC and

Correlation & Price change

A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with SRPT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NXTC
1D Price
Change %
NXTC100%
-0.61%
SRPT - NXTC
38%
Loosely correlated
-0.70%
ACET - NXTC
35%
Loosely correlated
-6.71%
VXRT - NXTC
27%
Poorly correlated
-7.14%
PMVP - NXTC
27%
Poorly correlated
-0.93%
MBIO - NXTC
27%
Poorly correlated
-0.97%
More